{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"1.68","upperLimit":"6.18","value":"1.68"},{"groupId":"OG001","lowerLimit":"2.83","upperLimit":"7.69","value":"2.83"}]}],"title":"patient 1"},{"categories":[{"measurements":[{"groupId":"OG000","value":"6.18"},{"groupId":"OG001","value":"7.69"}]}],"title":"patient 2"},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.71"},{"groupId":"OG001","value":"5.52"}]}],"title":"patient 3"},{"categories":[{"measurements":[{"groupId":"OG000","value":"5.42"},{"groupId":"OG001","value":"6.57"}]}],"title":"patient 4"},{"categories":[{"measurements":[{"groupId":"OG000","value":"4.73"},{"groupId":"OG001","value":"4.96"}]}],"title":"patient 5"},{"categories":[{"measurements":[{"comment":"only 5 patients have been analyzed in this arm","groupId":"OG000","value":"NA"},{"groupId":"OG001","value":"7.42"}]}],"title":"patient 6"}],"denoms":[{"counts":[{"groupId":"OG000","value":"5"},{"groupId":"OG001","value":"6"}],"units":"Participants"}],"description":"DOR was defined as the duration from the date of the best confirmed response for subjects who achieved CR or PR to the date of first documented evidence of PD (or relapse for subjects who experienced CR) over the duration of the study. DOR = (\\[Date of PD or date of censoring - Date of best response\\]+1)/30.44.","groups":[{"description":"vincristine: 0.4mg IV push on days 1 to 4; adriamycin: 9mg/m² IV push on days 1 to 4; dexamethasone: 40 mg daily days 1- 4/9-12/17-20 - cycle 1 / days 1-4/17-20 - subsequent cycle","id":"OG000","title":"VAD Treatment"},{"description":"bortezomib: 1.3 mg/m² intravenous (IV) bolus on days 1, 4, 8, and 11; adriamycin: 9mg/m² IV push on days 1 to 4; dexamethasone: 40 mg daily days 1- 4/9-12/17-20 - cycle 1 / days 1-4/17-20 - subsequent cycle","id":"OG001","title":"PAD Treatment"}],"paramType":"NUMBER","populationDescription":"Subjects in the ITT population (all subjects who received at least one dose of study drug and who had at least one post baseline efficacy parameter) were included.There was insufficient data to perform Kaplan Meier analysis (data available for 5 subjects in the VAD group and 6 subjects in the PAD group).","reportingStatus":"POSTED","timeFrame":"every 28 days during treatment period for up to 6 to 8 cycles","title":"Duration of Response (DOR)","type":"SECONDARY","unitOfMeasure":"months"}